Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 25, No 14 (May 10), 2007: pp. 1898-1907
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.10.3085

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gridelli, C.
Right arrow Articles by Schild, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gridelli, C.
Right arrow Articles by Schild, S. E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

REVIEW ARTICLE

Lung Cancer in the Elderly

Cesare Gridelli, Corey Langer, Paolo Maione, Antonio Rossi, Steven E. Schild

From the Division of Medical Oncology, "S.G. Moscati" Hospital, Avellino, Italy; Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA; and the Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ

Address reprint requests to Cesare Gridelli, MD, Division of Medical Oncology, "S.G. Moscati" Hospital, Contrada Amoretta, 83100 Avellino, Italy; e-mail: cgridelli{at}libero.it

Purpose Elderly patients often have comorbidities and other characteristics that make the selection of treatment daunting.

Methods We have reviewed the available evidence in the literature to gauge the results of therapy for elderly lung cancer patients.

Results The beneficial results achieved with adjuvant chemotherapy in the general population with early non–small-cell lung cancer (NSCLC) cannot be automatically extrapolated to the elderly, who are at higher risk of toxicity. Retrospective analyses of combined chemoradiotherapy in locally advanced NSCLC patients suggest equivalent therapeutic benefit for younger and older patients, despite heightened toxicity. There have been no elderly-specific phase III trials for locally advanced NSCLC. For advanced NSCLC, on the basis of evidence-based data, single-agent chemotherapy remains the standard of care for nonselected elderly patients. However, retrospective analyses suggest that the efficacy of platinum-based combination chemotherapy is similar in fit older and younger patients, with increased but acceptable toxicity for elderly patients. In limited-disease small-cell lung cancer (SCLC), sequential chemoradiotherapy is clearly less toxic compared with a standard concurrent approach, but our assessment of treatment is hindered by the absence of prospective elderly-specific trials. Although prophylactic cranial irradiation has emerged as a standard strategy, it should be omitted in patients with cognitive impairment. In extensive SCLC, etoposide in combination with either cisplatin or carboplatin has emerged as standard treatment; hematopoietic support may be necessary.

Conclusion With the exception of advanced NSCLC, prospective elderly-specific studies are lacking. Available data suggest that outcomes in the fit elderly mirror results observed in younger patients, although toxicity is generally worse.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Jpn J Clin OncolHome page
K. Okamoto, I. Okamoto, K. Takezawa, I. Tachibana, M. Fukuoka, Y. Nishimura, and K. Nakagawa
Cisplatin and Etoposide Chemotherapy Combined with Early Concurrent Twice-daily Thoracic Radiotherapy for Limited-disease Small Cell Lung Cancer in Elderly Patients
Jpn. J. Clin. Oncol., October 16, 2009; (2009) hyp137v1.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. A. Nikolova, I. A. Asangani, L. D. Nelson, D. P.M. Hughes, D. R. Siwak, G. B. Mills, A. Harms, E. Buchholz, L. R. Pilz, C. Manegold, et al.
Cetuximab Attenuates Metastasis and u-PAR Expression in Non-Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
Cancer Res., March 15, 2009; 69(6): 2461 - 2470.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
D. D. Ruysscher, A. Botterweck, M. Dirx, M. Pijls-Johannesma, R. Wanders, M. Hochstenbag, A.-M. C. Dingemans, G. Bootsma, W. Geraedts, J. Simons, et al.
Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study
Ann. Onc., January 1, 2009; 20(1): 98 - 102.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. M. Lichtman, L. Balducci, and M. Aapro
Geriatric Oncology: A Field Coming of Age
J. Clin. Oncol., May 10, 2007; 25(14): 1821 - 1823.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online